Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis

Diagnostic Microbiology and Infectious Disease

Volumn 80, Issue 3, 2014, Pages 222-226

  Tsai, Hsih Yeh ^a   Chen, Yen Hsu ^b   Tang, Hung Jen ^c   Huang, Chi Chang ^d   Liao, Chun Hsing ^a   Chu, Fang Yeh ^a   Chuang, Yin Ching ^c   Sheng, Wang Huei ^e   Ko, Wen Chien ^d   Hsueh, Po Ren ^e  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bacteremia; Carbapenems; Extended spectrum lactamase; Piperacillin tazobactam; Proteus mirabilis; Treatment outcomes

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CHOICE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING PROTEUS MIRABILIS; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BACTEREMIA; CLINICAL TRIAL; DRUG EFFECTS; ENZYMOLOGY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROTEUS INFECTIONS; PROTEUS MIRABILIS; SECRETION (PROCESS); SURVIVAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CARBAPENEMS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PROTEUS INFECTIONS; PROTEUS MIRABILIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84927572428     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.07.006     Document Type: Article

References (26)

1. Bouchillon S.K., Badal R.E., Hoban D.J., Hawser S.P. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther 2013, 35:872-877.
2. Centers for Disease Control and Prevention (CDC) Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013, 62:165-170.
3. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
4. Chen C.Y., Chen Y.H., Lu P.L., Lin W.R., Chen T.C., Lin C.Y. Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes. J Microbiol Immunol Infect 2012, 45:228-236.
5. Chow J.W., Fine M.J., Shlaes D.M., Quinn J.P., Hooper D.C., Johnson M.P., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing. 20th informational supplement. CLSI document M100-S20 2010, [Wayne PA].
7. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing. 22th informational supplement. CLSI document M100-S23 2013, [Wayne PA].
8. Datta P., Gupta V., Arora S., Garg S., Chander J. Epidemiology of extended-spectrum β-lactamase, AmpC, and carbapenemase production in Proteus mirabilis. Jpn J Infect Dis 2014, 67:44-46.
9. De Rosa F.G., Pagani N., Fossati L., Raviolo S., Cometto C., Cavallerio P., et al. The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection 2011, 39:555-561.
10. Endimiani A., Luzzaro F., Brigante G., Perilli M., Lombardi G., Amicosante G., et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005, 49:2598-2605.
11. Fraenkel C.J., Ullberg M., Bernander S., Ericson E., Larsson P., Rydberg J., et al. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals. Scand J Infect Dis 2006, 38:853-859.
12. Gavin P.J., Suseno M.T., Thomson R.B., Gaydos J.M., Pierson C.L., Halstead D.C., et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006, 50:2244-2247.
13. Gupta V., Bansal N., Singla N., Chander J. Occurrence and phenotypic detection of class A carbapenemases among Escherichia coli and Klebsiella pneumoniae blood isolates at a tertiary care center. J Microbiol Immunol Infect 2013, 46:104-108.
14. Jean S.S., Hsueh P.R., Lee W.S., Yu K.W., Liao C.H., Chang F.Y., et al. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009. Int J Antimicrob Agents 2013, 41:457-462.
15. Kurihara Y., Hitomi S., Oishi T., Kondo T., Ebihara T., Funayama Y., et al. Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis. J Infect Chemother 2013, 10.1007/s10156-013-0563-3.
16. Lee J.C., Lee N.Y., Lee H.C., Huang W.H., Tsui K.C., Chang C.M., et al. Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae and their emergence in the community. J Microbiol Immunol Infect 2012, 45:127-133.
17. Liu S.W., Chang H.J., Chia J.H., Kuo A.J., Wu T.L., Lee M.H. Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study. J Microbiol Immunol Infect 2012, 45:113-119.
18. McCue J.D. Gram-negative bacillary bacteremia in the elderly: incidence, ecology, etiology, and mortality. J Am Geriatr Soc 1987, 35:213-218.
19. Peterson L.R. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 2008, 14(Suppl. 1):181-184.
20. Rupp M.E., Fey P.D. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003, 63:353-365.
21. Schneider I., Markovska R., Marteva-Proevska Y., Mitov I., Markova B., Bauernfeind A. Detection of CMY-99, a novel acquired AmpC-Type β-lactamase, and VIM-1 in Proteus mirabilis isolates in Bulgaria. Antimicrob Agents Chemother 2014, 58:620-621.
22. Sheng W.H., Badal R.E., Hsueh P.R. Distribution of extended-spectrum beta-lactamases, AmpC beta-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2013, 57:2981-2988.
23. Tam V.H., Gamez E.A., Weston J.S., Gerard L.N., Larocco M.T., Caeiro J.P., et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008, 46:862-867.
24. Tumbarello M., Sanguinetti M., Montuori E., Trecarichi E.M., Posteraro B., Fiori B., et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta -lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51:1987-1994.
25. United States Food and Drug Administration (FDA) Highlights of prescribing information Tygacil Available at, [Accessed 6 April 2010]. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm132714.htm.
26. Wang S.S., Lee N.Y., Hsueh P.R., Huang W.H., Tsui K.C., Lee H.C., et al. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Microbiol Immunol Infect 2011, 44:282-288.